Ketamine for PTSD in Military Populations: Systematic Review Insights

Ketamine Shows Preliminary Efficacy for PTSD in Military and Veteran Groups

Recent systematic review evidence indicates that ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, may reduce symptoms of post-traumatic stress disorder (PTSD) in military and veteran populations. The review, published on October 7, 2026 (OpenAlex: W7220862115), synthesized eight studies (N=383), including five randomized controlled trials (RCTs) and three uncontrolled or observational studies. Most studies reported reductions in PTSD symptoms following ketamine or esketamine administration, with one small open-label study in veterans showing an 80% remission rate after six infusions. However, the review emphasizes that these findings are preliminary and must be interpreted with caution due to methodological limitations.

Mechanism of Action and Context in PTSD Treatment

Ketamine's rapid-acting antidepressant and anti-PTSD effects are believed to stem from its antagonism of NMDA receptors, leading to downstream increases in glutamate signaling and synaptic plasticity. This mechanism is distinct from traditional first-line PTSD treatments, such as selective serotonin reuptake inhibitors (SSRIs) and trauma-focused psychotherapies, which often have limited efficacy in military and veteran populations. The review highlights that ketamine may offer a novel therapeutic avenue for individuals who do not respond to existing treatments. Importantly, the studies included in the review often involved participants with chronic, treatment-resistant PTSD—a group for whom new options are urgently needed.

Policy and Research Implications: The Need for Rigorous Trials

Current evidence does not support widespread clinical adoption of ketamine for PTSD in military and veteran populations. The systematic review underscores the lack of large, well-controlled trials with adequate follow-up and standardized safety reporting. Most included studies had small sample sizes (largest N=99), short observation periods, and considerable heterogeneity in dosing, administration routes, and outcome measures. Notably, the largest reported effect size (d'=2.17) came from a small, uncontrolled study, limiting its generalizability. The review calls for multi-site, phase III randomized controlled trials with robust safety monitoring and longer-term follow-up to clarify ketamine's risk-benefit profile in these high-risk groups. As of October 2026, neither the U.S. Department of Veterans Affairs (VA) nor the U.S. Food and Drug Administration (FDA) has approved ketamine specifically for PTSD, and its use remains off-label in this context.

Risks, Unknowns, and Real-World Challenges

Adverse effects associated with ketamine in these studies included transient dissociation, increases in blood pressure, and other hemodynamic changes during infusion, which typically resolved post-administration. Importantly, none of the reviewed studies reported cognitive decline with repeated ketamine dosing, though follow-up durations were generally short (weeks to a few months). The review notes inconsistent safety reporting across studies, with some failing to systematically assess or report adverse events. This inconsistency complicates risk assessment, especially for populations with comorbidities common in military and veteran groups. A less-discussed but critical challenge is the potential for selection bias: individuals with more severe or complex PTSD may be underrepresented in clinical trials, limiting the applicability of findings to real-world clinical settings.

Looking Forward: Priorities for Clinical and Policy Decision-Making

Ketamine's potential to address unmet needs in PTSD treatment for military and veteran populations is promising but unproven. The systematic review makes clear that, while short-term symptom reductions are possible, the field lacks the rigorous, large-scale evidence required for policy change or clinical guideline updates. Key priorities include standardizing outcome measures, ensuring comprehensive safety monitoring, and enrolling more representative samples in future trials. For researchers and policymakers, the review highlights a non-obvious but crucial decision criterion: the need to balance rapid access to novel therapies with the imperative for robust evidence, particularly in high-risk, high-need populations. Until such evidence is available, clinicians and institutions should approach off-label ketamine use for PTSD with caution, clear informed consent, and careful monitoring.

How we research: This article was researched and written by Dr. Alex M. Carter, PhD, Psychedelic Research Journal clinical trials editor. Reviewed by Dr. Lisa Tran, MD, on 2026-10-10. Primary sources include the systematic review itself and direct trial registry records where available.